
FDA Provides CRL to Ivonescimab/Chemotherapy for Pretreated EGFR+ NSCLC
A complete response letter was given to ivonescimab for patients with previously treated EGFR-mutated NSCLC.
A complete response letter (CRL) has been given by the FDA to biologics license application (BLA) for ivonescimab plus platinum-containing chemotherapy for patients with locally advanced or metastatic non–small cell lung cancer (NSCLC) with prior EGFR tyrosine kinase inhibitor (TKI) therapy, according to a press release from Summit Therapeutics.1
The reason for the CRL indicated by the FDA was the lack of effectiveness with the progression-free survival (PFS) and the absence of statistical significance of an overall survival (OS) improvement Therefore, it did not support a positive benefit-risk profile for an approval. The press release highlighted that there are no currently approved FDA regiments that demonstrate statistical significance with OS in this setting.
“As a cancer survivor, I understand firsthand how important it is for patients to have access to multiple treatment options, particularly when they are facing diseases with significant unmet medical needs,” Maky Zanganeh, MBA, DDS, president and co-chief executive officer of Summit Therapeutics, said in the press release. “Every additional treatment option matters. It represents another opportunity for patients and their families, especially those who have exhausted existing therapies or have limited alternatives. Our responsibility as an industry is to continue advancing science, challenging conventional thinking, and bringing innovative medicines to patients in need. For me, our mission is deeply personal to bring our innovative medicine to patients who may benefit most.”
What data supported the BLA of ivonescimab plus chemotherapy?
Supporting data for the approval came from the phase 3 HARMONi trial (NCT06396065), which assessed ivonescimab/chemotherapy vs placebo plus chemotherapy among patients with EGFR-mutated NSCLC. Topline data showed…
According to detailed findings presented at the
Investigators performed the primary overall survival (OS) analysis for the HARMONi trial in April 2025.3 Data from that analysis showed a median OS of 16.8 months with the ivonescimab combination and 14.0 months with placebo/chemotherapy (HR, 0.79; 95% CI, 0.62-1.01; P = .057). An additional analysis performed in September 2025, in which patients from Western countries were followed to increase their time on the study, showed an OS benefit that was consistent with previous evaluation (HR, 0.78; 95% CI, 0.62-0.98; P = .0332). In an additional analysis with a data cutoff of June 2026, the HR for OS was 0.76 for the full intent-to-treat population as well as the Western population subgroup.
What is the safety of ivonescimab plus chemotherapy?
Safety data presented at WCLC showed that 9.6% of patients in the ivonescimab arm experienced grade 3 or higher immune-related adverse effects (IRAEs) vs 6.0% of those in the placebo arm. The most common IRAEs of any grade in the ivonescimab arm included hypothyroidism (8.3%), hyperthyroidism (4.1%), increased aspartate aminotransferase levels (3.2%), and elevated alanine aminotransferase levels (2.8%).
“The efficacy of [ivonescimab] was consistent across subgroups, with perhaps more benefit [in patients] with brain metastases,” Jonathan Goldman, MD, professor of medicine in the Division of Hematology/Oncology, director of Clinical Trials in Thoracic Oncology, and associate director of Early Drug Development at the University of California Los Angeles, stated in his presentation of the data at WCLC 2025.2
What is ivonescimab, and how was the HARMONi trial designed?
Developers designed ivonescimab as an investigational bispecific antibody that combines the effects of PD-1 blockade with the antiangiogenesis impacts of blocking VEGF. The agent’s tetravalent structure is intended to facilitate higher avidity in the tumor microenvironment compared with other therapeutic options.
Investigators of the phase 3 HARMONi trial assessed ivonescimab plus chemotherapy vs placebo plus chemotherapy in patients with EGFR-mutated, locally advanced or metastatic nonsquamous NSCLC who previously received a third-generation EGFR-TKI. Patients were randomly assigned 1:1 to receive 20 mg/kg of ivonescimab every 3 weeks plus carboplatin at area under the curve 5 every 3 weeks across four 21-day cycles and pemetrexed at 500 mg/m2 every 3 weeks (n = 219) or placebo in combination with the carboplatin and pemetrexed at the same dosing levels (n = 219).
The trial’s coprimary end points were PFS and OS per independent radiology review committee assessment using RECIST v1.1 criteria. Secondary end points included overall response rate, duration of response, and safety.
In January 2026, the
The press release also highlighted that there are 5 ongoing clinical trials assessing ivonescimab across multiple disease states including colorectal cancer, urothelial carcinoma, and renal cell carcinoma.
References
- Summit Therapeutics provides update regarding ivonescimab biologics license application. News release. November 15, 2026. Accessed November 16, 2026. https://tinyurl.com/bdz7kayy
- Goldman JW, Passaro A, Laskin J, et al. Ivonescimab vs placebo plus chemo, phase 3 in patients with EGFR+ NSCLC progressed with 3rd gen EGFR-TKI treatment: HARMONi. Presented at: International Association for the Study of Lung Cancer 2025 World Conference on Lung Cancer; September 6-9, 2025; Barcelona, Spain. Abstract 4808.
- Ivonescimab plus chemotherapy shows consistent, favorable overall survival results in western and Asian patients in updated analysis from global phase III HARMONi study. News release. Summit Therapeutics Inc. July 22, 2026. Accessed November 5, 2026. https://tinyurl.com/2kz36ux7
Related to this article








